Variants with greater impact
Analyzes 155 genes associated with hereditary cancers, heart disease and other conditions with preventive implications.
Genetic prevention
Transform genetic predisposition into a prevention plan.
Longevo brings together monogenic variants, risk scores and pharmacogenomics to support tracking, habits and medical monitoring in a more individualized way.
- Scope
- More than 100 conditions
- Risk
- Monogenic and polygenic
- Sample
- Mouth swab
- Application
- Prevention and pharmacogenomics
Three-layer prevention
From predisposition to the next step.
Genetics alone does not determine the future of health. Its value lies in being integrated with age, history, tests and habits to support decisions proportionate to risk.
Integrated polygenic risk
Includes scores for breast cancer and cardiovascular risk, interpreted together with clinical data and within the limits of the reference population.
Pharmacogenomics and screening
Organizes findings that can support discussion about medications, habits and screening strategies with the assistant team.
Clinical scope
More than 100 conditions organized by areas of care.
Conditions were selected for their relevance to prevention, screening or treatment. The presence of a predisposition does not equate to a diagnosis.
01
Hereditary cancer
Breast and ovarian, colorectal and polyposis, prostate, endocrine tumors, melanoma and other predisposing syndromes.
02
Cardiovascular health
Cardiomyopathies, arrhythmias, aortic diseases, hereditary cholesterol and polygenic risk of heart attack.
03
mental health
Psychiatric pharmacogenomics, including response to antidepressant classes and atomoxetine-related adjustment.
04
Neurological health
Neurodegenerative conditions, including predisposition to Alzheimer's disease, and neuromuscular diseases.
05
Metabolism and endocrinology
Hereditary metabolic diseases, hemochromatosis and selected endocrine disorders.
06
Skin and hair
Predisposition to melanoma, skin cancer and other conditions included in the current version of the panel.
Clinical interpretation
A report that separates risk, evidence and action.
The result organizes the findings by health area and highlights the points that deserve discussion with the doctor.
- Relevant monogenic findings in the genes evaluated
- Contextualized risk scores
- Suggested next actions for clinical discussion
Real excerpt from the NeoReport demonstration environment, cut without personal data.
Test day
From sample collection to preventive plan.
A clinical flow to integrate sequencing, curation and screening recommendations.
-
01
Scheduling and preparation
The team guides the request, preparation and receipt of the kit when necessary.
-
02
Sample collection
Buccal swab collected as per kit instructions.
-
03
Laboratory analysis
Sequencing, bioinformatics processing and specialized curation.
-
04
Preventive report
The result brings together findings, limits and points for clinical discussion.
The release period is confirmed at the time of request and begins after receipt and acceptance of the sample.
Optional medical follow-up
Do you want to integrate the result into a medical evaluation?
Longevo Premium maintains the same genetic content as Longevo and adds pre-examination consultation, post-examination consultation and annual clinical reassessment of data for four consecutive years.
Get to know Longevo PremiumFrequently asked questions
Before ordering.
Do I need a medical request?+
A doctor's order is not required to purchase Longevo. Still, the result should be shared with a professional who knows your history and can contextualize it.
What conditions are analyzed?+
155 genes and more than 100 conditions are evaluated in areas such as hereditary cancer, cardiology, neurology, metabolism and pharmacogenomics, in addition to selected scores.
What happens if there is a high risk outcome?+
The team guides the clinical discussion, eventual confirmation and referral. Tests, habits or medications should not be changed solely based on the genetic report.
How is sample collection done?+
sample collection is done with a mouth swab. The team informs the preparation, identification, shipping and traceability of the sample.
Is the test covered by a health plan?+
The test is private. NeoGenomica provides documentation for requesting reimbursement when the agreement contract allows.
Does a negative result eliminate future risk?+
No. The test evaluates a defined scope and does not replace recommended screening for age, sex, family history and clinical factors.
Personalized prevention
Start with information that can guide choices.
Receive the kit at home and count on the team to understand the process and the result.
Catalog information
Technical data of Longevo
Assessment of hereditary predispositions relevant to preventive care.
- Applications
- Hereditary cancer, Personalized prevention, Cardiovascular risk, Pharmacogenomics
- Accepted samples
- peripheral blood, Mouth swab (preferred), DNA extraído
- Estimated deadline
- Deadline subject to confirmation by the technical team.
- Methodology
- Genetic sequencing, bioinformatics processing and specialized clinical curation.
- Analytical scope
- 155 genes and more than 100 conditions, including hereditary cancer, cardiovascular health, neurology, metabolism, endocrinology and pharmacogenomics.
- Medical request
- Not mandatory
Requirements
Does not require a doctor's order for purchase. The result must be contextualized with age, history, tests and habits by a health professional.
Limitations
Predisposition does not equate to diagnosis. Polygenic scores must be interpreted within the limits of the reference population.
